Annals of the New York Academy of Sciences

Cover image for Vol. 1053 Neuroprotective Agents: Seventh International Conference

August 2005

Volume 1053 Neuroprotective Agents: Seventh International Conference

Pages xi–xi, 1–518

  1. Preface

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Preface (page xi)

      WILLIAM SLIKKER JR., RUSSELL J. ANDREWS and BRUCE TREMBLY

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00001.x

  2. Session I. The Human Experience of Neuroprotection

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Protective Effect of Neuromonitoring during Cardiac Surgery (pages 12–19)

      HARVEY L. EDMONDS JR.

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00003.x

    2. Neuropsychiatric Alterations in MDMA Users : Preliminary Findings (pages 20–27)

      RONALD I. HERNING, WARREN BETTER, KIMBERLY TATE and JEAN L. CADET

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00004.x

    3. Panel of Biomarkers Predicts Stroke (page 30)

      D T LASKOWITZ, R BLESSING, J FLOYD, W D WHITE and J R LYNCH

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00006.x

    4. Evaluating Neuroprotective Agents in Coronary Artery Bypass Surgery (page 31)

      STANTON NEWMAN

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00007.x

  3. Session II. Mechanisms of Neuroprotection (1)

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Delineating and Understanding Cerebellar Neuroprotective Pathways : Potential Implication for Protecting the Cortex (pages 39–47)

      XUAN WU, XUEYING JIANG, ANN M. MARINI and ROBERT H. LIPSKY

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00009.x

    2. A Role for Calpain in Optic Neuritis (pages 48–54)

      M KELLY GUYTON, ERIC A. SRIBNICK, SWAPAN K. RAY and NAREN L. BANIK

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00010.x

    3. Antiapoptotic and Anti-inflammatory Mechanisms of Heat-Shock Protein Protection (pages 74–83)

      MIDORI A. YENARI, JIALING LIU, ZHEN ZHENG, ZINAIDA S. VEXLER, JONG EUN LEE and RONA G. GIFFARD

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00012.x

    4. Neuroprotection by NGF in the PC12 In Vitro OGD Model : Involvement of Mitogen-Activated Protein Kinases and Gene Expression (pages 84–96)

      RINAT TABAKMAN, HAO JIANG, IRIS SHAHAR, HADAR ARIEN-ZAKAY, ROBERT A. LEVINE and PHILIP LAZAROVICI

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00013.x

  4. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Microglial NADPH Oxidase Mediates Leucine Enkephalin Dopaminergic Neuroprotection (pages 107–120)

      LIYA QIN, YUXIN LIU, XUN QIAN, JAU-SHYONG HONG and MICHELLE L. BLOCK

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00016.x

    2. Effect of Neuroprotective Drugs on Gene Expression in G93A/SOD1 Mice (pages 121–136)

      SHEILA IGNACIO, DAN H. MOORE, ANDREW P. SMITH and NANCY M. LEE

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00017.x

    3. Brain Response to Injury and Neurodegeneration : Endogenous Neuroprotective Signaling (pages 137–147)

      NICOLAS G. BAZAN, VICTOR L. MARCHESELLI and KASIE COLE-EDWARDS

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00018.x

    4. Early Effects of Modulating Nuclear Factor-κB Activation on Traumatic Spinal Cord Injury in Rats (pages 148–150)

      OCTAVIO JIMÉNEZ-GARZA, JAVIER CAMACHO, ANTONIO IBARRA, ANGELINA MARTÍNEZ and GABRIEL GUÍZAR-SAHAGÚN

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00019.x

  5. Session IV. Role of Carnitines and Other Agents in Neuroprotection

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Mechanisms of Ischemic Neuroprotection by Acetyl-l-carnitine (pages 153–161)

      SANTINA A. ZANELLI, NINA J. SOLENSKI, ROBERT E. ROSENTHAL and GARY FISKUM

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00021.x

    2. Identification of Rat Hippocampal mRNAs Altered by the Mitochondrial Toxicant, 3-NPA (pages 162–173)

      BEATA D. PRZYBYLA-ZAWISLAK, BRETT T. THORN, SYED F. ALI, RICHARD A. DENNIS, ANTONINO AMATO, ASHRAF VIRMANI and ZBIGNIEW K. BINIENDA

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00022.x

    3. l-Carnitine and Neuroprotection in the Animal Model of Mitochondrial Dysfunction (pages 174–182)

      ZBIGNIEW BINIENDA, BEATA PRZYBYLA-ZAWISLAK, ASHRAF VIRMANI and LARRY SCHMUED

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00023.x

  6. Session V. Neuroprotective Approaches and Models

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Circulatory Arrest as a Model for Studies of Global Ischemic Injury and Neuroprotection (pages 205–219)

      LARS WIKLUND, HARI SHANKER SHARMA and SAMAR BASU

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00027.x

    2. Possible Neuroprotective Mechanism of Human Neuroglobin (pages 220–230)

      KEISUKE WAKASUGI, CHIHIRO KITATSUJI and ISAO MORISHIMA

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00028.x

    3. The Impact of Aging, Dietary Restriction, and Glucocorticoids on ApoE Gene Expression in Rat Brain (pages 231–232)

      S RUZDIJIC, M PEROVIC, A MLADENOVIC, D MILANOVIC, L RAKIC, S PETANCESKA and S KANAZIR

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00029.x

  7. Session VI. Neuroprotective Agents and Mechanisms

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Saposin C: Neuronal Effect and CNS Delivery by Liposomes (pages 237–246)

      ZHENGTAO CHU, YING SUN, CHIA YI KUAN, GREGORY A. GRABOWSKI and XIAOYANG QI

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00031.x

    2. Mechanisms of Disease: Motoneuron Disease Aggravated by Transgenic Expression of a Functionally Modified AMPA Receptor Subunit (pages 269–286)

      ROHINI KUNER, ANTHONY J. GROOM, GERALD MÜLLER, HANS-CHRISTIAN KORNAU, VANYA STEFOVSKA, IRIS BRESINK, BETTINA HARTMANN, KARSTEN TSCHAUNER, STEFAN WAIBEL, ALBERT C. LUDOLPH, CHRYSANTHY IKONOMIDOU, PETER H. SEEBURG and LECHOSLAW TURSKI

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00034.x

  8. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Potentially Neuroprotective and Therapeutic Properties of Nitrous Oxide and Xenon (pages 289–300)

      JACQUES H. ABRAINI, HÉLÈNE N. DAVID and MARC LEMAIRE

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00036.x

    2. Chronic Exposure to Nitrous Oxide Increases [3H]MK801 Binding in the Cerebral Cortex, but Not in the Hippocampus of Adult Mice (pages 301–308)

      NATASCHA SOMMER, CARMELO ROMANO and VESNA JEVTOVIC-TODOROVIC

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00037.x

    3. Systems Biology/Systems Toxicology : Application to Developmental Neurotoxicology/Neuroprotection (pages 309–310)

      WILLIAM SLIKKER JR., ZENGJUN XU and CHENG WANG

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00038.x

    4. Antioxidative Effect of Vitamin D3 on Zinc-Induced Oxidative Stress in CNS (pages 319–329)

      ANYA M. Y. LIN, K B CHEN and P L CHAO

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00040.x

  9. Session VIII. Mechanisms of Neuroprotection (2)

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl-2 Family Members with PKC Pathway (pages 348–355)

      ORLY WEINREB, TAMAR AMIT, ORIT BAR-AM, ORLY CHILLAG-TALMOR and MOUSSA B. H. YOUDIM

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00043.x

    2. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70 (pages 356–375)

      SILVIA MANDEL, EDNA GRUNBLATT, PETER RIEDERER, NINETTE AMARIGLIO, JASMINE JACOB HIRSCH, GIDEON RECHAVI and MOUSSA B. H. YOUDIM

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00044.x

    3. Immune-Modulating Effects of Melatonin, N-Acetylserotonin, and N-Acetyldopamine (pages 386–393)

      MARY C. PERIANAYAGAM, GREGORY F. OXENKRUG and BERTRAND L. JABER

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00046.x

    4. N-Acetyldopamine Inhibits Rat Brain Lipid Peroxidation Induced by Lipopolysaccharide (pages 394–399)

      GREGORY F. OXENKRUG and PURA J. REQUINTINA

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00047.x

  10. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Acrylamide Stimulates Glutamine Uptake in Fischer 344 Rat Astrocytes by a Mechanism Involving Upregulation of the Amino Acid Transport System N (pages 435–443)

      QI WU, MARTA SIDORYK, LYSETTE MUTKUS, MAGDALENA ZIELIŃSKA, JAN ALBRECHT and MICHAEL ASCHNER

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00052.x

    2. Effects of Acrylamide on Primary Neonatal Rat Astrocyte Functions (pages 444–454)

      MICHAEL ASCHNER, QI WU and MARVIN A. FRIEDMAN

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00053.x

    3. Neuroprotection by Platelet-Activating Factor Antagonism (pages 455–456)

      XIAOHUA TIAN and NICOLAS G. BAZAN

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00054.x

  11. Session X. Novel Approaches to Neuroprotection

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Expression of Prostaglandin E2 Synthases in Mouse Postnatal Cortical Neurons (pages 460–471)

      VALENTINA ECHEVERRIA, DAVID L. GREENBERG and SYLVAIN DORÉ

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00056.x

    2. Novel Neuroprotective Tripeptides and Dipeptides (pages 472–481)

      ALAN I. FADEN, SUSAN M. KNOBLACH, VILEN A. MOVSESYAN, PAUL M. LEA IV and IBOLJA CERNAK

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00057.x

    3. Neuroprotection in the PNS: Erythropoietin and Immunophilin Ligands (pages 491–501)

      AHMET HÖKE and SANJAY C. KESWANI

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00059.x

  12. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations

    1. Top of page
    2. Preface
    3. Session I. The Human Experience of Neuroprotection
    4. Session II. Mechanisms of Neuroprotection (1)
    5. Session III. Neuroprotection in Inflammation-Related Neurodegenerative Diseases
    6. Session IV. Role of Carnitines and Other Agents in Neuroprotection
    7. Session V. Neuroprotective Approaches and Models
    8. Session VI. Neuroprotective Agents and Mechanisms
    9. Session VII. The NMDA Receptor as a Target for Neurotoxicity and Neuroprotection
    10. Session VIII. Mechanisms of Neuroprotection (2)
    11. Session IX. Sensitive Targets for Neurotoxicity and Neuroprotection
    12. Session X. Novel Approaches to Neuroprotection
    13. Session XI. Workshop PBPK/PD Models for Developing Humans: Risk Assessment Strategies and Research Recommendations
    1. Improving Predictive Modeling in Pediatric Drug Development: Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling (pages 505–518)

      WILLIAM SLIKKER JR., JOHN F. YOUNG, RICHARD A. CORLEY, DAVID C. DORMAN, RORY B. CONOLLY, THOMAS B. KNUDSEN, BRIAN L. ERSTAD, RICHARD H. LUECKE, ELAINE M. FAUSTMAN, CHARLES TIMCHALK and DONALD R. MATTISON

      Version of Record online: 28 JUN 2008 | DOI: 10.1111/j.1749-6632.2005.tb00061.x

SEARCH

SEARCH BY CITATION